<DOC>
	<DOCNO>NCT01278602</DOCNO>
	<brief_summary>The aim study prove R-ESHAP regimen follow autologous stem cell transplantation salvage treatment patient refractory relapse diffuse large B-cell lymphoma effective .</brief_summary>
	<brief_title>R-ESHAP Followed Autologous Transplantation Refractory Relapsed Diffused Large B-cell Lymphoma</brief_title>
	<detailed_description>The standard treatment patient refractory relapse diffuse large B-cell lymphoma salvage chemotherapy follow autologous transplantation responsive patient . However , standard salvage chemotherapy remain uncertain . This study evaluate efficacy safety R-ESHAP regimen multi-center basis .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<criteria>Age range : 1865 year old Histological confirm diffuse large Bcell lymphoma Refractory first relapse disease Prior anthracycline exposure Measurable disease ECOG performance status 01 Life expectancy 3 month Bone marrow function : ANC≧1.5×109/L , PLT≧100×109/L , Hb≧90g/L Liver function : total bilirubin , ALT AST &lt; 1.5×UNL Renal function : Cr &lt; 1.5×UNL , CCR≧50ml/min No contraindication transplantation Evidence CNS bone marrow involvement More 1 type chemotherapy regimens exposure High level HBV DNA Contraindication highdose methylprednisolone Pregnant lactate woman History malignancy except cure basal cell carcinoma skin carcinoma insitu uterine cervix History allergic reaction/hypersensitivity rituximab Significant active infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Diffuse large B-cell lymphoma</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>R-ESHAP</keyword>
	<keyword>Autologous stem cell transplantation</keyword>
</DOC>